A global, randomized Phase 3 trial of ONZEALD (etirinotecan pegol) in patients with advanced breast cancer and brain metastases

Trial Profile

A global, randomized Phase 3 trial of ONZEALD (etirinotecan pegol) in patients with advanced breast cancer and brain metastases

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2016

At a glance

  • Drugs Etirinotecan pegol (Primary)
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Nektar Therapeutics
  • Most Recent Events

    • 06 Jun 2016 New trial record
    • 01 Jun 2016 According to a Nektar Therapeutics media release, this trial may serve as a potential registrational study for approval of Onzeald in the US. This trial is being performed to satisfy EMA's requirement for additional controlled data with the MAA for conditional approval.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top